CER-001

Phase 2Small molecule

CCerenis Therapeutics, SA

CER-001 is one of 82 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

AtherosclerosisActive, not recruiting

Homozygous Familial HypercholesterolemiaActive, not recruiting

Acute Coronary SyndromePhase 2

Active, not recruiting

AtherosclerosisPhase 2

Active, not recruiting

Homozygous Familial HypercholesterolemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

183 competitors in Acute Coronary Syndrome

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

5 2

Lovenox

Sanofi

Phase 3

4 3

Eliquis

Bristol-Myers Squibb

Phase 3

3 4

Avapro

Sanofi

Phase 3

1 5

Farxiga

AstraZeneca

Phase 3

1 6

Fluzone

Nesina

1 8

Acetylsalicylic Acid

Bayer

Phase 3

5 9

Ranexa

MMenarini International Operations Luxembourg SA

Phase 3

1 10

Glucophage

EMD Serono

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia1 trial

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects

Completed·CCerenis Therapeutics, SA·Phase 2·NCT01412034·23 enrolled

Acute Coronary Syndrome1 trial

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

Completed·CCerenis Therapeutics, SA·Phase 2·NCT01201837·507 enrolled

Regression1 trial

Exploratory Study of Plaque Regression

Completed·CCerenis Therapeutics, SA·Phase 2·NCT01515241·10 enrolled

Atherosclerosis1 trial

CER-001 Atherosclerosis Regression ACS Trial

Completed·CCerenis Therapeutics, SA·Phase 2·NCT02484378·301 enrolled

Unspecified1 trial

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Terminated·CCerenis Therapeutics, SA·Phase 3·NCT02697136·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CER-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CER-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CER-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cerenis Therapeutics, SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCerenis Therapeutics, SA

CER-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia1 trial

Acute Coronary Syndrome1 trial

Regression1 trial

Atherosclerosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News